Niflumic acid is a drug used for joint and muscular pain. It is categorized as an inhibitor of cyclooxygenase-2. In experimental biology, it has been employed to inhibit chloride channels. It has also been reported to act on GABA-A and NMDA channels and t + some more technical info. Chemically, niflumic acid has the molecular formula C13H9F3N2O2 and a molecular weight of approximately 282.22 g mol, is a weakly acidic, low water solubility, small molecule that is absorbed orally, undergoes hepatic metabolism, and is eliminated via renal and biliary routes; its pharmacological profile includes COX-2 mediated reduction of prostaglandin synthesis together with ion channel modulation that can alter neuronal and epithelial excitability, which is relevant both to its analgesic properties and to its experimental use as a chloride channel blocker.
Parent: Niflumic Acid
Parent: Niflumic Acid
Parent: Niflumic Acid
Parent: Niflumic Acid
Parent: Niflumic Acid
Typical quality specifications for niflumic acid active pharmaceutical ingredient control related substances to minimize patient risk and ensure consistent performance; typical limits are individual identified impurities not more than 0.2 percent w w by HPLC, any single unspecified impurity not more than 0.1 percent, and total impurities not more than 1.0 percent. Common related compounds to monitor include: the desfluoro analog (impurity A, limit 0.2 percent), the N oxide or N oxide-like oxidation product (impurity B, limit 0.1 percent), the deaminated or aniline-type impurity (impurity C, limit 0.2 percent), and low level synthesis-related residues (each not to exceed 0.1 percent); residual solvents should meet ICH Q3C class limits and heavy metals should be controlled to pharmacopeial ppm levels.
Niflumic acid is used clinically for relief of joint and muscular pain and inflammation; it is also used in research to probe chloride channel function and certain neuronal receptor activities.
Niflumic acid reduces prostaglandin production by inhibiting cyclooxygenase-2 activity and also modulates ion channels, including inhibition of certain chloride channels and reported interactions with GABA-A and NMDA receptors, producing both anti inflammatory and ion channel mediated effects.
Concomitant use of niflumic acid and paracetamol is commonly practiced for additive analgesic effect, but any combination should be used under medical guidance to account for overall dosing, potential for increased adverse effects, and individual contraindications such as hepatic impairment or drug interactions.
